Science News

WASHINGTON--(BUSINESS WIRE)--Dr. Krishnan Suthanthiran and his TeamBest Global family of companies—recognized innovators in cost-effective technologies for the diagnosis/treatment of cancer and vascular diseases, including theranostics—have issued an open call for deeper collaboration with the Association of Radiation Oncologists of India (AROI). Suthanthiran founded the International Society of Therapeutic Radiology and Oncology (ISTRO) under the Best Cure Foundation (BCF) and the Brachytherap...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on November 28, 2025. One individual was hired by Adicet in November 2025 and granted new hire non-qualified stock options to purchase 20,600 shares of Adicet’s common stock with an exercise price of $0.65 per share, the closing price of...

DUBLIN--(BUSINESS WIRE)--The "Fallopian Tube Cancer Market - A Global and Regional Analysis: Focus on Type, Treatment Type, End User, and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. The global fallopian tube cancer market is being driven by several key factors. Rising awareness and early screening initiatives, supported by public health campaigns and improved diagnostic imaging technologies, are enabling earlier detection of gynaecologic cance...

TORONTO, Ontario--(BUSINESS WIRE)--Celltrion, Inc. today announced that Health Canada has approved Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all indications approved for Eylea.1 “Today’s approval lays a solid foundation for Celltrion’s expansion into the Canadian ophthalmology market and represents a significant milestone in diversifying the company’s portfolio,” said Jungyong Shin, Managing Director at Celltrion...

LUGANO, Switzerland--(BUSINESS WIRE)--SFI Health reports publication of the results from a study about the impact of Long-Chain Polyunsaturated Fatty Acids on literacy skills in children....

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats at two upcoming investor conferences: 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 9:35 a.m. ET in Miami, FL...

MANHASSET, N.Y.--(BUSINESS WIRE)--Recent reports show that one in seven first responders have probable post-traumatic stress disorder (PTSD) in response to routine duties with prevalence increasing after responding to a crisis. To improve our understanding and the well-being of these essential heroes, researchers at Northwell Health’s Feinstein Institutes for Medical Research, Stony Brook University and Texas A&M University received a $3.37-million grant from the National Institute of Menta...

DUBLIN--(BUSINESS WIRE)--The "Antibody Contract Development & Manufacturing Organization Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering. The global antibody contract development and manufacturing organization (CDMO) market is poised for substantial growth, with its value estimated at USD 21.1 billion in 2024 and projected to soar to USD 45.8 billion by 2033. This represents a CAGR of 9.38% from 2025 to 2033, driven by a surge in demand for monoclonal antibodies...

DUBLIN--(BUSINESS WIRE)--The "DNA Methylation Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering. The global DNA methylation market, valued at an estimated USD 1.64 billion in 2024, is anticipated to experience robust growth, reaching USD 5.52 billion by 2033. This represents a compound annual growth rate (CAGR) of 14.73% from 2025 to 2033. Market expansion is predominantly driven by the increasing prevalence of cancer and other chronic conditions. According to the Nat...

DUBLIN--(BUSINESS WIRE)--The "Healthcare Contract Research Organization Market Forecast to 2033" has been added to ResearchAndMarkets.com's offering. The global healthcare contract research organization (CRO) market is projected to expand significantly from USD 55.84 billion in 2024 to USD 105.73 billion by 2033, at a CAGR of 7.42%. This growth is propelled by increased investments in drug development, an upsurge in R&D activities, expanding regulatory requirements, the globalization of cli...